n = 372 | Crs < 35.4 n = 186 | Crs > 35.4 n = 186 | P valuea |
---|---|---|---|
Age, mean ± SD | 63.5 ± 10 | 63.2 ± 10.8 | 0.78 |
Gender, men, n (%) | 130 (70) | 154 (83) | 0.005 |
Body mass index, kg/m2, mean ± SD | 29.9 ± 5.1 | 29.5 ± 5 | 0.47 |
Hypertension, n (%) | 116 (62) | 94 (51) | 0.02 |
Pulmonary chronic disease, n (%) | 24 (13) | 26 (14) | 0.88 |
Charlson comorbidity index, median (IQR) | 1 (0–2) | 1 (0–2) | 0.18 |
Charlson comorbidity index | 0.11 | ||
0 | 69 (37) | 86 (46) | |
1 | 53 (29) | 38 (20) | |
≥ 2 | 64 (34 | 62 (33) | |
Time from symptoms onset, days, median (IQR) | 7 (5–10) | 8 (5–10) | 0.02 |
Coinfection, n (%) | 19 (10) | 23 (12) | 0.62 |
PaO2/FiO2 (mmHg), mean ± SD | 123 ± 48 | 132 ± 53 | 0.07 |
Tidal volume (ml/kg IBW), mean ± SD n = 180/185 | 6.2 ± 0.9 | 6.3 ± 0.8 | 0.12 |
PEEP (cmH2O), mean ± SD | 11.1 ± 2.9 | 12 ± 2.6 | 0.002 |
Plateau pressure (cmH2O), median (IQR) | 26 (23–28) | 22 (20–24) | < 0.001 |
Driving Pressure (cmH2O), median (IQR) | 14 (12–16) | 9.5 (8–11) | < 0.001 |
Inhaled nitric oxide, n (%) | 21 (11) | 23 (12) | 0.87 |
Prone positioning, n (%) | 152 (82) | 147 (79) | 0.51 |
Neuromuscular blocking agents, n (%) | 162 (87) | 151 (81) | 0.16 |
Antiviral treatment, n (%) | 143 (77) | 158 (85) | 0.06 |
Corticosteroidsb, n (%) n = 175/182 | 34 (19) | 43 (24) | 0.37 |
Macrolides | 112 (60) | 116 (62) | 0.75 |